Europe
The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.
A new and more easily transmissible strain of COVID-19, dubbed VUI-202012/01, has now been reported in at least six different countries and global territories since it first appeared in the U.K. a few weeks ago.
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
Shares of Mesoblast Limited are down more than 30% in premarket trading following the company’s disappointing announcement late Thursday regarding its stem-cell therapy trial in ventilator-dependent patients with COVID-19 patients who have moderate to severe acute respiratory distress syndrome.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments.
PRESS RELEASES